Pieris Pharmaceuticals (NASDAQ:PIRS) Now Covered by StockNews.com

Investment analysts at StockNews.com initiated coverage on shares of Pieris Pharmaceuticals (NASDAQ:PIRS) in a note issued to investors on Sunday. The brokerage set a “hold” rating on the biotechnology company’s stock.

Pieris Pharmaceuticals Stock Performance

Shares of PIRS stock opened at $0.15 on Friday. Pieris Pharmaceuticals has a one year low of $0.14 and a one year high of $1.01. The company’s 50-day moving average is $0.17 and its 200 day moving average is $0.19. The company has a market capitalization of $14.45 million, a price-to-earnings ratio of -0.52 and a beta of 0.48.

Pieris Pharmaceuticals (NASDAQ:PIRS) last announced its quarterly earnings data on Friday, March 29th. The biotechnology company reported ($0.05) EPS for the quarter. Pieris Pharmaceuticals had a negative net margin of 57.33% and a negative return on equity of 90.17%. The firm had revenue of $1.30 million for the quarter.

Institutional Trading of Pieris Pharmaceuticals

An institutional investor recently raised its position in Pieris Pharmaceuticals stock. CM Management LLC grew its stake in shares of Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) by 18.1% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 649,400 shares of the biotechnology company’s stock after acquiring an additional 99,400 shares during the quarter. CM Management LLC owned about 0.66% of Pieris Pharmaceuticals worth $194,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 40.11% of the company’s stock.

Pieris Pharmaceuticals Company Profile

Pieris Pharmaceuticals, Inc, a biotechnology company, discovers and develops biotechnological applications. The company focuses on the development of its 4-1BB bispecifics immuno-oncology (IO) programs. Its clinical pipeline consists of IO bispecifics, including S095012 (PRS-344), a bispecific Mabcalin compound targeting PD-L1 and 4-1BB in partnership with Les Laboratoires Servier and Institut de Recherches Internationales Servier; SGN-BB228 (PRS-346), a CD228 x 4-1BB bispecific antibody-Anticalin compound targeting CD228 and 4-1BB in partnership with Pfizer Inc; and BOS-342 (PRS-342), a GPC3 x 4-1BB bispecific Mabcalin compound targeting GPC3 and 4-1BB in partnership with Boston Pharmaceuticals, which are in phase 1 studies.